Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cantargia AB ( (SE:CANTA) ) has provided an announcement.
Cantargia AB has appointed Dr. Wolfram Dempke as its new Chief Medical Officer, bringing over 30 years of experience in hematology and oncology. Dr. Dempke’s extensive background in drug research and development, particularly in pancreatic cancer, is expected to enhance Cantargia’s ongoing efforts in oncology. This strategic appointment is likely to strengthen Cantargia’s position in the biotechnology industry, potentially leading to more effective treatments for cancer and inflammatory diseases.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform centered on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary oncology program, nadunolimab (CAN04), is being clinically studied in combination with chemotherapy, targeting pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. The company also has a second development program, CAN10, which addresses serious autoimmune and inflammatory diseases.
Average Trading Volume: 6,556,162
Technical Sentiment Signal: Hold
Current Market Cap: SEK650.1M
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.